ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Houston, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Houston, TX, USA:

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non...

Enrolling
EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients
Drug: NXP900
Drug: Osimertinib

Phase 1

Nuvectis Pharma

Houston, Texas, United States and 2 other locations

3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCL...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Houston, Texas, United States and 36 other locations

with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) wi...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: pemetrexed
Drug: Tislelizumab

Phase 2

BeiGene
BeiGene

Houston, Texas, United States and 61 other locations

N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...

Active, not recruiting
Stage IIIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Procedure: Surgery
Radiation: Radiotherapy

Phase 2

Alliance Foundation Trials

Houston, Texas, United States and 8 other locations

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

Houston, Texas, United States and 61 other locations

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Houston, Texas, United States and 230 other locations

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or m...

Enrolling
Non-Small Cell Lung Cancer
Drug: Dato-DXd
Drug: Ramucirumab

Phase 2

AstraZeneca
AstraZeneca

Houston, Texas, United States and 82 other locations

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Sugar Land, Texas, United States and 263 other locations

to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non...

Enrolling
Non Small Cell Lung Cancer
Drug: HLX43 DOSE 2 (2.5 mg/kg)
Drug: HLX43 DOSE 1 (2.0 mg/kg)

Phase 2

Henlius Pharmaceuticals

Houston, Texas, United States and 1 other location

growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC).The study will compris...

Enrolling
Non-Small Cell Lung Cancer
Biological: BNT116
Biological: Bispecific antibody for PD-L1 and VEGF-A

Phase 1

BioNTech
BioNTech

Houston, Texas, United States and 44 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems